BSP:BMYB34 (USA)  
Bristol-Myers Squibb Co logo

Bristol-Myers Squibb Co

R$ 359.34 (0%) Sep 23
P/E:
23.49
P/B:
4.63
Market Cap:
R$ 767.28B ($ 145.86B)
Enterprise V:
R$ 925.29B ($ 175.90B)
Volume:
-
Avg Vol (2M):
1.16K
Also Trade In:
Volume:
-
Market Cap R$:
767.28B
Market Cap $:
145.86B
PE Ratio:
23.49
Avg Vol (2-Month):
1.16K
Enterprise Value R$:
925.29B
Enterprise Value $:
175.90B
PB Ratio:
4.63
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download

Business Description

Description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Financials (Next Earnings Date:2022-10-26)

BSP:BMYB34's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil R$) 247,104.19
EPS (TTM) (R$) 15.961
Beta 0.11
Volatility % 25.77
14-Day RSI 44.79
14-Day ATR (R$) 4.910393
20-Day SMA (R$) 358.736
12-1 Month Momentum % 21.06
52-Week Range (R$) 302.02 - 418.5
Shares Outstanding (Mil) 2,135.26

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 8
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Bristol-Myers Squibb Co Filings

Document Form Filing Date
No Filing Data

Bristol-Myers Squibb Co Analysis

Share your research